Literature DB >> 9784115

Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.

M Singer1, W J Ryan, B Saha, B R Martin, R K Razdan.   

Abstract

The synthesis and pharmacological profile of several cyano (1a-e) and carboxamido (2a-h) side-chain-substituted analogues of 1', 1'-dimethyl-Delta8-THC are described. Commercially available cyano compound 3 was transformed to the resorcinol 6 in a three-step sequence. Condensation of 6 with p-menth-2-ene-1,8-diol formed the THC 7a which, with sodium cyanide/DMSO, gave 1b. Protection of the phenol in 7a as the MOM derivative provided the common intermediate 8 for the synthesis of 1a,c,e. Compound 1d was also synthesized from 7a via the aldehyde 9a. Base hydrolysis of 1b gave the acid 10 which, via its acid chloride and subsequent treatment with the appropriate amine, formed the target compounds 2a-h. The pharmacological profile indicated that the cyano analogues 1a-e had very high CB1 binding affinity (0.36-13 nM) and high in vivo potency as agonists. Two analogues (1a,b) had extremely high potency in the mouse tetrad tests. The dimethylcarboxamido analogue 2a showed a similar profile to 1a,b. The high potency was also retained in analogue 2c. In contrast the sulfonamide analogue 2d was unique as it had greater affinity than Delta9-THC, yet it was practically devoid of agonist effects. This study suggests that the incorporation of a cyano or an amide substituent in the side chain of Delta8-THC-DMH can enhance potency and can also lead to compounds with a unique profile which have high binding affinity and are practically devoid of agonist effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784115     DOI: 10.1021/jm9803875

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.

Authors:  Peter J Crocker; Anu Mahadevan; Jenny L Wiley; Billy R Martin; Raj K Razdan
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

2.  Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.

Authors:  G Griffin; S Williams; M M Aung; R K Razdan; B R Martin; M E Abood
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model.

Authors:  Spyros P Nikas; Jolanta Grzybowska; Demetris P Papahatjis; Avgui Charalambous; Ali R Banijamali; Ravi Chari; Pusheng Fan; Therapia Kourouli; Sonyuan Lin; Albert J Nitowski; Gilbert Marciniak; Yan Guo; Xiuyan Li; Chia-Lin J Wang; Alexandros Makriyannis
Journal:  AAPS J       Date:  2004-10-19       Impact factor: 4.009

4.  Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Authors:  Jenny L Wiley; Christopher S Breivogel; Anu Mahadevan; Roger G Pertwee; Maria Grazia Cascio; Daniele Bolognini; John W Huffman; D Matthew Walentiny; Robert E Vann; Raj K Razdan; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2010-11-27       Impact factor: 4.432

5.  O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.

Authors:  R G Pertwee; T M Gibson; L A Stevenson; R A Ross; W K Banner; B Saha; R K Razdan; B R Martin
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

7.  The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.

Authors:  Eric W Bow; John M Rimoldi
Journal:  Perspect Medicin Chem       Date:  2016-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.